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RACIAL DISPARITIES IN THE TREATMENT OF BLACK WOMEN WITH 
BREAST CANCER IN THE UNITED STATES 
HALEY URBACH 
 
ABSTRACT 
 Breast cancer affects over three million women in the United States, but this 
disease burden is not shared equally across all races. Black women, in particular, are 
diagnosed with more advanced cancer at a younger age and experience a 
disproportionately high mortality rate compared to white women. Factors that contribute 
to such disparity include socioeconomic status, tumor biology, age, insurance status, 
comorbidities, obesity, patients’ reproductive history and barriers to quality care. These 
factors alone, however, do not account for all the racial differences in mortality and 
outcomes experienced by black women. There is a growing body of literature that 
indicates black women are not receiving the same treatment and care as white women. 
Black women are less likely to receive surgery, radiation therapy, hormone therapy and 
targeted therapy than white women. Black women are also more likely to experience 
delays in the initiation of treatment, early discontinuation of treatment and overall 
guideline non-concordant care. The current literature has presented widespread racial 
disparities in the treatment of black women with breast cancer. Future research needs to 
focus on tangible interventions such as physician bias training and patient navigators to 
mitigate the inequity of care in the treatment of breast cancer.  
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INTRODUCTION 
 
 Breast cancer is the most common form of cancer to affect women in the United 
States. It is estimated that 266,120 new cases of breast cancer will be diagnosed and 
40,900 women will die of their disease in 2018 (“Female Breast Cancer - Cancer Stat 
Facts” 2018). Women living in the US have a 12.5% chance of developing breast cancer 
in their lifetime. This risk has steadily increased over the decades from 1 in 11 women 
diagnosed with breast cancer in the 1970’s to 1 in 8 women today (American Cancer 
Society 2017). Breast cancer, however, does not affect all populations equally. Minority 
women are diagnosed with more advanced breast cancer and have higher rates of 
mortality (Ooi, Martinez, and Li 2011) (Figure 1). The data indicates that black women 
are more likely to die from breast cancer at all ages than any other race/ethnicity 
(American Cancer Society 2017). The remainder of this paper will focus specifically on 
racial differences in the treatment of breast cancer between black and white women.  
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Figure 1: Trends in Female Breast Cancer Incidence and Mortality by 
Race/Ethnicity (Adapted from “USCS Data Visualizations” 2017). Rates are per 
100,000 persons and are age-adjusted to the 2000 US standard population. Breast cancer 
incidence rates are increasing for black women and other minorities but rates are 
decreasing for white women. The mortality rate was 42% higher in black women than 
white women for the 2011 - 2015 time period (DeSantis et al. 2017). 
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The study of breast cancer racial disparities in the US has been ongoing for many 
decades now. Despite years of research, the fact remains that black women are not 
receiving the same treatment and outcomes as their white counterparts. Breast cancer 
incidence rates continue to rise in black women 0.4% each year, but rates have stabilized 
in white women since 2005 (DeSantis et al. 2017). Relative 5-year survival rates for 
women with breast cancer are improving, but there is still a marked difference between 
black women and white women with 83% and 92% respective 5-year survival rates 
(DeSantis et al. 2017). Furthermore, as of 2015, breast cancer incidence rates continue to 
be higher for white women overall, yet mortality rates are higher for black women 
(Figure 2). Specifically, mortality rates were 39% higher for black women compared to 
white women in 2015 (DeSantis et al. 2017). As long as these trends in incidence, 
mortality and survival remain in place, further research on the causes of these black-white 
health disparities is warranted. The remainder of this section will summarize the staging 
and classification systems for breast cancer, current treatments for breast cancer and 
factors contributing to racial disparities in breast cancer treatment and outcomes.  
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Figure 2: Female Breast Cancer Incidence and Mortality by Race (Adapted from 
Street 2017). Incidence rates are higher for white women than black women, yet black 
women have a higher mortality rate.  
 
Breast Cancer Classification and Staging 
 
 Breast cancer is defined as an abnormal growth of malignant cells in the 
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diagnosis, cancer is either confined to the tissue of origin (In Situ) or has spread to 
surrounding tissues, becoming invasive. According to the Breast Cancer Facts and 
Figures 2017-2018 published by the American Cancer Society (ACS), 80% of all breast 
cancer is invasive. There are currently two major classification systems used for staging 
cancer, Tumor, Node, Metastasis (TNM) and Surveillance, Epidemiology and End 
Results (SEER) (Table 1). These staging systems are used to quantify cancer prognosis 
and aid in determining appropriate treatment. Based on SEER data from 2002 to 2008, 
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from the Concord-2 Study, Miller and colleagues found that survival of distal tumors was 
25.7% for white women and 17.1% for black women and survival of regional tumors was 
83.5% for white women and 71.8% for black females (Miller et al. 2017). These 
differences in disease stage and prognosis highlight an important disparity in the field of 
breast cancer research. 
 
Table 1. Cancer Staging (American Cancer Society 2017) 
TNM SEER Description 
0 In Situ Abnormal cells remain at the site of origin 
I Local 
Abnormal cells have penetrated nearby tissue but 
remains in the breast 
II Local/Regional 
Cancerous cells have moved from the breast to 
nearby lymph nodes 
III Regional 
Cancerous cells have penetrated further lymph 
nodes and tissue outside of the breast 
IV Distant 
Cancerous cells have metastasized to tissue distal 
from the breast 
 
 In addition to staging cancer based on the spread from the site of origin, breast 
cancer can be classified according to its molecular subtype. Genome profiling and 
microarray technologies led to the discovery of molecular subtypes (Perou et al. 2000). 
This newer classification system is used to tailor treatment for breast cancer based on the 
receptors expressed in the tumor. There are four major subtypes based on two receptors 
that are frequently tested for, including the Hormone Receptors (HR - estrogen and 
progesterone) and the Human Epidermal Growth Factor Receptor 2 (HER2) (Table 2). 
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Luminal A breast cancer is a low-grade cancer with the best prognosis of the four types 
while Luminal B tends to be high-grade and more aggressive. Triple Negative Breast 
Cancer (TNBC) is very aggressive and has no identifiable receptor targets making it the 
subtype with the worst prognosis (Lukong 2017). HER2+ enriched tumors are also 
aggressive cancers, but they have advanced targeted therapies, giving them better longer-
term prognosis (Haque et al. 2012). Luminal A is the most common subtype among all 
women, but TNBC has a higher prevalence among black women than white women 
(Perou and Børresen-Dale 2011). As genetic profiling techniques continue to improve, 
there is hope that additional molecular subtypes will be discovered creating new targets 
for therapy. 
 
Table 2. Molecular Subtypes of Cancer (Adapted from American Cancer Society 
2017). 
Major Types Molecular 
Profile 
Overall 
Prevalence 
Prevalence 
in White 
Women 
Prevalence 
in Black 
Women 
Luminal A HR+/HER2- 71% 72.5% 59.1% 
Luminal B HR+/HER2+ 12% 12.4% 12.7% 
Triple Negative 
/Basal Like 
HR-/HER2- 12% 10.6% 21.8% 
HER2 enriched HR-/HER2+ 5% 4.4% 6.4% 
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Breast Cancer Treatments 
 Treatments have dramatically progressed since breast cancer was first identified 
and continue to improve steadily as technology advances. The progression of 
chemotherapy agents since the 1970’s has enabled more effective treatment of breast 
cancer. Genome profiling to determine molecular subtype has also revolutionized the 
treatment of breast cancer allowing for the development of targeted therapies. Figure 3 
illustrates important advancements in the history of breast cancer treatment (Figure 3).  
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Figure 3: Timeline of Important Breast Cancer Treatment Developments (Lukong 
2017; Ades et al. 2017; Lakhtakia and Chinoy 2014; Lakhtakia and Burney 2015; 
“History of Cancer Screening and Early Detection” 2014). 
1894 Surgeon, William Halsted, develops the radical mastectomy
1937 National Cancer Act of 1937 led to the formation of the National Cancer Institute
1967 Elwood Jensen discovered estrogen receptors
1974 Doxorubicin (anthracycline) proven to work as a chemotherapy agent
1976 Mammograms first recommended for breast cancer screening by the    American Cancer Society 
1981 Veronesi et al. published a study advocating for the use of radiotherapy  after breast surgery
1982 HER2+/neu gene first identified
1986 Tamoxifen was approved by the FDA as an anti-estrogen therapy for post-menopausal women
1994 Paclitaxel (taxane) introduced as some of the first chemotherapy drugs
1995 BRCA1 and BRCA2 genes discovered
1996 Sentinel Lymph Node Biopsy became popularized; Anastrozole (aromatase inhibitor) approved for the treatment of HR+ breast cancer
1998 Capecitabine introduced as a chemotherapy drug for metastatic cancer; Trastuzumab created as a targeted therapy for HER2+ 
2000 Perou et al. published their seminal paper on molecular subtypes using DNA microarrays
2002 Fulvestrant introduced as an anti-estrogen drug used as a second line therapy after tamoxifen has failed
2007 Lapatinib first approved as HER2-inhibitor that works to suppress cell proliferation in HER2+ disease
2012 Pertuzumab approved to be used in conjunction with trastuzumab and docetaxal for treatment of HER2+ metastatic breast cancer
2013 Trastuzumab emtansine (T-DMI) was approved in 2013 to also treat HER2+ breast cancer
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Treatment for breast cancer is largely determined by the molecular subtype and 
stage of the cancer (Figure 4). Early-stage breast cancer is usually targeted locoregionally 
with breast conserving surgery (BCS) and adjuvant treatment such as radiation therapy 
(RT) or chemotherapy to reduce the chance of recurrence (Harbeck and Gnant 2017). 
Standard adjuvant treatment for early stage HR+ breast cancer is endocrine therapy (ET) 
over the course of 5-10 years. Tamoxifen is usually given to premenopausal patients and 
tamoxifen/aromatase inhibitors for postmenopausal women (Harbeck and Gnant 2017). 
Chemotherapy is recommended for patients with TNBC or HER2+ enriched subtypes 
(Carey et al. 2007). For early breast cancer, anthracylines and taxanes (paclitaxel and 
docetaxel) are the recommended chemotherapy agents to be given over the course of 18-
24 weeks. Neoadjuvant systemic therapy using chemotherapy, endocrine therapy or 
targeted therapy is the standard of care for tumors that are too large for breast conserving 
therapy (Harbeck and Gnant 2017). For TNBC, patients typically receive neoadjuvant 
anthracycline-taxane chemotherapy with the possible addition of platinum. Patients with 
HER2+ cancers are given trastuzumab for one year in addition to anthracycline-taxane 
chemotherapy (Harbeck and Gnant 2017).  
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Figure 4: Treatment of Early Stage Breast Cancer (Adapted from Harbeck and 
Gnant 2017). The indicated treatment courses vary according to the subtype of breast 
cancer. Mutations in the BRCA1/BRCA2 tumor suppressor genes are rare, but confer an 
elevated risk of 69-72% of developing breast cancer compared to the average population 
(Kuchenbaecker et al. 2017). Genetic testing for BRCA1/2 is recommended for patients 
with a family history suggesting a high risk of BRCA1/2. Patients who test positively for 
BRCA1/2 may consider a prophylactic mastectomy (Gabai-Kapara et al. 2014). 
 
Late-stage or metastatic breast cancer is also treated with chemotherapy, 
hormonal therapy and targeted therapy (Figure 5). Patients with metastatic breast cancer 
typically receive systemic therapy followed by locoregional therapy as appropriate. In 
metastatic HR+ /HER2- breast cancer, endocrine therapy including tamoxifen, aromatase 
inhibitors, fulvestrant, and progestins is recommended (Lukong 2017). For 
premenopausal patients, ovarian suppression is also suggested. For patients with 
metastatic HR- /HER2+, anti-HER2 therapy, trastuzumab, and taxane chemotherapy is 
the standard treatment course (Lukong 2017). As additional molecular subtypes are 
discovered, further targeted therapies will hopefully become available.  
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Figure 5: Treatment of Metastatic Breast Cancer (Adapted from Harbeck and 
Gnant 2017).  
Factors Contributing to Healthcare Disparities 
 In examining risk factors for breast cancer, there is an attempt to determine the 
causes of unequal distribution of aggressive breast cancer subtypes across races. A 
review on health disparities and TNBC, published by Newman and colleagues in 2017 
identified the following factors as contributing to the racial disparities in breast cancer 
outcomes: poverty/socioeconomic status (SES), insurance status, lactation and 
reproductive history, obesity, comorbid conditions such as diabetes, alcohol and tobacco 
use, and allostatic load (Newman and Kaljee 2017).  
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A study based on the SEER database found that SES and tumor characteristics 
(e.g., molecular subtype, tumor size, grade and sentinel lymph node involvement) were 
two of the major differentiating factors between black and white women (Ren et al. 
2018). SES is often tied to a patient’s insurance status and patients with no insurance or 
public insurance such as Medicaid are less likely to receive the same quality of care as 
commercially insured patients (Wittayanukorn et al. 2015). Notably, research has 
indicated that after controlling for insurance status, over 70% of the racial differences in 
outcomes remained (Jemal et al. 2017). Socioeconomic status and insurance status are 
two of the largest hurdles to overcome on the path to racial equity in breast cancer 
treatment.  
Furthermore, lactation and reproductive history have a complicated interplay with 
breast cancer risk. Breast feeding for longer has been shown to protect against basal-like 
breast cancer and TNBC (Brawley 2013; Ma et al. 2017). Higher parity without breast 
feeding has also been linked to an increased risk of TNBC and black women on average 
have more children than white women (Palmer et al. 2011; Martin et al. 2017). Although 
breastfeeding rates are increasing for black women, studies have found that white women 
are more likely to breastfeed their children and for longer than black women in the US. 
(Williams, Mohammed, and Shields 2016; Anstey et al. 2017). Policies that support 
breastfeeding may help reduce the unequal rates of TNBC across ethnicities. 
Additionally, lifestyle factors such as diet and daily activity levels can have a 
major impact on breast cancer occurrence. Black women in the US have a higher 
likelihood of being obese, and obesity is linked to increased rates of postmenopausal 
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breast cancer (Brawley 2013). Increased alcohol consumption and, to a lesser extent, 
tobacco use are associated with higher rates of breast cancer, as well (Williams et al. 
2016). Fortunately, lifestyle factors are points of targetable intervention for physicians 
and healthcare providers to reduce rates of breast cancer.  
Lastly, allostatic load is the concept that repeated stressors across a person’s life 
can accumulate to present as biological dysregulation (Williams et al. 2016). Data from 
the Black Women’s Health Study indicated that women who experience racial 
discrimination on the job had a 20% higher chance of developing breast cancer (Taylor et 
al. 2007). Life stressors, especially those resulting from racial discrimination are 
experienced unequally across the US population. Mitigating the negative effects of 
allostatic load may yet prove to be one of the greatest challenges in the work to eliminate 
racial disparities in healthcare as it will ultimately require a systemic intervention to 
alleviate.  
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SPECIFIC AIMS 
 
The aims of this thesis are to: 
 
1. Provide an overview of racial disparities currently published in the breast cancer 
literature. 
2. Examine the racial disparities between black and white women specifically in the 
treatment of breast cancer and the resulting outcomes. 
3. Analyze the published literature for sources of future research and interventions to 
help mitigate racial disparities in the survival of black women with breast cancer.   
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PUBLISHED STUDIES 
 
Screening and Staging Disparities 
 
 One of the most crucial aspects of breast cancer treatment is early detection. 
Mammography remains the gold standard for initial screening and detection of breast 
cancer. According to the American Cancer Society, women ages 45 to 54 should have 
annual mammograms and women aged 55 and older should have a mammogram every 
other year. Based on SEER data from 2015, 50% of white women and 55% of black 
women had a mammogram in the past year (American Cancer Society 2017). A study by 
Silber et al. published in 2013 using data from the SEER-Medicare database, found that 
after matching for patient demographics (age, year of diagnosis, and SEER site), white 
women had a 12.2% higher chance of having been screened for breast cancer in the 6 to 
18 months prior to diagnosis compared to black women (Silber et al. 2013). However, 
many studies have found that screening mammography is statistically equivalent between 
black and white women (Newman and Kaljee 2017; Miller et al. 2017). In fact, a study 
focused on women in South Carolina found that black women have higher rates of breast 
cancer screening but were still more likely to be diagnosed with late stage breast cancer 
(Samson et al. 2016). Therefore, breast cancer screening rates are generally considered 
equivalent in black and white women among experts in the field.  
 After a woman has a positive mammogram, completing a sentinel lymph node 
biopsy (SLNB) is the standard of care. If patients have a positive lymph node biopsy, 
they should then receive either an axillary lymph node dissection or axillary radiotherapy 
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(Harbeck and Gnant 2017). A study published by Reeder-Hayes et. al in 2011, examining 
SEER-Medicare data from 2000 to 2002, found that when comparing across all ages, 
black women were about half as likely to receive SLNB as white women. This same 
study found that Medicare did not protect black women from receiving reduced rates of 
SLNB, indicating that insurance status is unlikely to be a major determining factor for 
racial disparity in the receipt of SLNB (Reeder-Hayes et al. 2011). In a study of patients 
undergoing surgical treatment in New York, white women were statistically more likely 
to undergo a SLNB than minority patients (Bickell et al. 2006). SLNB is a crucial first 
step in determining the subtype of breast cancer which informs treatment, but the 
literature indicates that black women are receiving significantly lower rates of SLNB. 
Given the fact that black women are more likely to have lymph node involvement, the 
reduced rates of SLNB have the potential to dramatically impact diagnosis and therefore 
treatment outcomes in black women (Foy et al. 2018; Ren et al. 2018). 
 
Treatment Disparities 
 
There is a growing body of published literature that points to racial differences in 
the treatment courses of women with breast cancer. In 2017, Jemal and colleagues 
published a study in the Journal of Clinical Oncology analyzing factors associated with 
breast cancer in over 500,000 women aged 18 to 64 from the National Cancer Data Base 
with stage I-III breast cancer. They found that black patients were more likely to present 
with HR- tumors diagnosed at a later stage, with the tumors having grown larger and 
more aggressive. Their statistical analysis indicated that black women with HR+ breast 
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cancer had a 76.3% increased risk of death compared to white women. Insurance status 
accounted for over 30% of this increased risk of death (Figure 6). Jemal and colleagues 
found that after matching patients based on tumor characteristics (e.g. stage, tumor size, 
grade, histological type and hormone receptor status) over 20% of the excessive risk was 
eliminated. Comorbidities also played a significant role contributing 11.3% of the 
increased risk of death for HR+ and 3.8% for HR- breast cancer patients. Differences in 
treatment contributed to 4.8% and 3.6% of the increased risk of death from HR+ and HR- 
breast cancer respectively (Jemal et al. 2017).  
 
Figure 6: Effect of Adding Matched Variables on Breast Cancer Hazard Ratio for 
Black Women Versus White Women (Jemal et al. 2017). Matched variables included 
demographics (age and residence at diagnosis), patient’s comorbidities, insurance status, 
tumor characteristics (stage, size, and grade), and treatment received (surgery, radiation, 
chemotherapy, and/or hormone therapy). Error bars indicate a 95% Confidence Interval. 
Adding matched variables reduced the disparities between black and white women but 
did not fully eliminate differences. 
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The previously noted study published by Silber et al. in 2013 corroborates partial 
findings of Jemal and colleagues. Based on the SEER-Medicare database, researchers 
found that 12.6 % of black patients did not receive treatment for breast cancer while only 
5.9% of white patients did not receive treatment (Silber et al. 2013). Furthermore, the 
mean time to treat in demographically matched patients was 29.2 days for black women 
versus 22.5 for white women. Ultimately, two times as many black women did not 
receive treatment within three months compared to white women with similar tumor 
characteristics. (Silber et al. 2013). Additional studies have confirmed that black women 
tend to receive treatment delays that are longer than their white peers (Brawley 2013). 
Hoppe and colleagues published a study on patients with stage I breast cancer from the 
National Cancer Data Base analyzing time to treatment. They also found that black 
women had significant delays in time to treatment compared to white women with an 
average delay of 7.4 days (Figure 7) (Hoppe et al. 2018). Breast cancer continues to be a 
disease in which time to treatment is critical for positive outcomes (Chavez-MacGregor 
et al. 2016).  
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Figure 7: Delays in Initiation of Breast Cancer Treatment (Adapted from Hoppe et 
al. 2018). Black women experienced an average delay of 7.4 days in initiation of 
treatment compared to white women. Black women receiving surgery had the shortest 
delay in treatment initiation of 36.6 days while black women receiving radiation therapy 
had the longest delay in treatment relative to white women of 32.2 days. 
 
Additionally, Chen and Li published another SEER database study on the receipt 
of treatment in women aged 20 -70 years old with primary invasive stage I/II breast 
cancer and tumors less than 2 cm in size. For the study’s purposes, guideline concordant 
treatment was defined as mastectomy or breast conserving surgery followed by radiation 
therapy. The data indicated that black women were 30-40% more likely to receive 
treatment inconsistent with given guidelines than white women across all breast cancer 
subtypes (Figure 8). Black women were 30-60% less likely to receive guideline 
concordant treatment for all breast cancers apart from HER2+ enriched breast cancer than 
white women (Chen and Li 2015). Ultimately, black women had a higher probability of 
being diagnosed later and receiving improper treatment.  
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Figure 8: Percent of SEER Patients Receiving Guideline Concordant Treatment 
(Adapted from Chen and Li 2015). Percentage of patients receiving concordant and 
non-concordant treatment by breast cancer subtype. The different rates of non-concordant 
treatment between black and white women was statistically significant in all subtypes 
except HR-/HER2+. Asterisk indicates a statistically significant Odds Ratio (OR) with p-
value < 0.5.  
Surgery 
 
 For most patients with early-stage breast cancer, surgery is the first line of 
treatment. Depending on the size of the tumor, patients will either receive breast 
conserving surgery for smaller tumors or mastectomy for larger tumors. Black women are 
less likely to receive surgery including breast conserving surgery, mastectomy, 
prophylactic mastectomy and reconstruction when diagnosed with cancer (Foy et al. 
2018). In fact, 93.8% of white women have surgery compared to only 90.4% of black 
women, a statistically significant difference (Foy et al. 2018). This evidence indicates 
that black women are less likely to receive even standard treatments when first diagnosed 
with breast cancer. 
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Furthermore, the previously discussed study by Jemal et al. found that in the 
patient cohort with HR+ cancer, a greater portion of white patients received surgery 
compared to black patients (Jemal et al. 2017). In a study drawing on a population of 
military patients from the Department of Defense Central Cancer Registry and Military 
Health Systems (MHS) Data Repository, Eaglehouse and colleagues examined the 
average time to surgical treatment for women diagnosed with early stage breast cancer. 
The study team found that there was delay of 3.6 days and 9.4 days for black women 
compared to white women at the 75th percentile and 95th percentile for treatment times 
respectively. Although these length of delays may appear short, the patients in this study 
all had equal access to treatment via insurance so should present with minimal to no 
differences in time to treatment (Eaglehouse et al. 2019). There is a growing body of 
literature that indicates black women are not receiving adequate care, especially first line 
treatment such as surgery.  
Radiation Therapy 
 
 Following surgery, radiation therapy is often the next line of treatment as an 
adjuvant therapy to prevent cancer recurrence. A study conducted at the James Cancer 
Center in Columbus, Ohio by Foy and colleagues found that black women were 13.7% 
less likely to receive radiation therapy than white women among patients with regional 
disease (Foy et al. 2018). Similarly, analyzing SEER data from 2000 to 2006, Ooi and 
colleagues determined that black women with stage I or II breast cancer had a higher 
chance of not receiving radiation treatment following BCS (Ooi, Martinez, and Li 2011). 
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Additional research confirmed that after BCS, black women are 11% less likely to 
receive RT than white women (Bickell et al. 2006). A study of patients from the SEER-
Medicare Database similarly concluded that 53% of black patients and 61% of white 
patients received RT post-mastectomy (Fang et al. 2018). Jemal and colleagues also 
published consistent data, indicating that a greater portion of white patients with HR+ 
breast cancer received radiation therapy than black patients (Jemal et al. 2017). 
In a study based on SEER data of women aged 65+ with stage I-III breast cancer 
that received BCS, black women experienced the greatest delays in receiving RT. Black 
women had an odds ratio of 0.62 for initiation of RT within 12 months compared to white 
women. However, after adjusting for patient characteristics, geographic distance to RT 
was one of the greater predictors of RT initiation (Wheeler et al. 2012). Radiation therapy 
is a crucial step in the treatment of breast cancer, the dramatic disparities presented 
throughout the literature can have a profound impact on patient outcomes.  
Chemotherapy 
 
Chemotherapy is typically given as an adjuvant therapy after surgery, as a 
neoadjuvant therapy before surgery or as a systemic therapy for cancer that is wide 
spread. If given after surgery, adjuvant chemotherapy should be started within 3-4 weeks 
(Harbeck and Gnant 2017). Based on data from over 10,000 patients in the SEER-
Medicare database, only 3.7% of black women received anthracycline and taxane 
chemotherapy medication compared to 5.0% of white women matched on initial 
presentation (Silber et al. 2013). Additionally, black women are less likely to receive 
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adjuvant chemotherapy than white women with an odds ratio of 0.87 according to data 
from over 400,000 patients in the National Cancer Database (Freedman et al. 2011).  
However, not all studies have found that black women are less likely to receive 
chemotherapy than white women. In fact, a study of patients with stage I breast cancer 
from the National Cancer Data Base concluded that black women underwent 
chemotherapy more often than white women at a rate of 31.1% vs 21.9% respectively 
(Hoppe et al. 2018). However, this finding was among women with stage I breast cancer 
for which surgery is the standard treatment course (Harbeck and Gnant 2017). 
Additionally, a study of women diagnosed in 2012 with stage IIB-IV cancer from the 
National Cancer Institute (NCI) Patterns of Care Study found that after adjusting for 
covariates such as age at diagnosis, there was no difference in the receipt of 
chemotherapy based on race for patients with stage IIIB-C breast cancer. Black women 
with stage IV cancer even had a slightly higher chance of receiving chemotherapy 
(Enewold et al. 2018). Furthermore, analysis of adjuvant chemotherapy received at the 
Henry Ford Health Systems in Detroit, Michigan between 1996 and 2005 by Simon and 
colleagues indicated that, overall, black women were 5% more likely to receive adjuvant 
chemotherapy than white women. However, black women experienced a statistically 
significant delay in the initiation of adjuvant chemotherapy of 5.3 days and white women 
were more likely to be treated within 60 days (Simon et al. 2012). Additionally, a meta-
analysis by Green and colleagues found that black patients and white patients received 
the same dosing for chemotherapy (Green et al. 2018). The receipt of chemotherapy is a 
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complex component of breast cancer treatment and one that requires additional studies to 
determine the extent of racial disparities.  
Hormone Therapy 
 
 Endocrine therapy is one of the major forms of treatment for HR+ breast cancer, 
the most prevalent form of breast cancer across all races. Nonadherence to endocrine 
therapy can have dire outcomes including faster times to recurrence, increased medical 
costs and overall reduced quality of life (McCowan et al. 2013). Based on patients that 
completed a two year follow up for Phase III of the Carolina Breast Cancer Study, 23.7% 
of black women reported underuse of ET, compared to only 15.9% of white women. 
Black women were also two times as likely to be non-adherent to ET (Wheeler et al. 
2018). Furthermore, black women have a lower chance of starting adjuvant endocrine 
therapy (AET) within a year of diagnosis than white women (Farias and Du 2017). 
Additional SEER data has demonstrated that white women have an odds ratio of 3.63 
compared to black women for initiation of AET but race did not significantly impact 
adjuvant endocrine therapy persistence (Friese et al. 2013). Based on data from 
OptumInsurance claims, black women were 32% less likely to be adherent to hormonal 
therapy. This disparity, however, was reduced to 19% when adjusting for net worth 
(Hershman et al. 2015). Additional studies have found that black women with HR+ breast 
cancer were 9% less likely to have ET than white women (Bickell et al. 2006). This 
statistic is particularly startling as patients with HR+ breast cancer are the most 
responsive to endocrine therapy treatments.  
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Nevertheless, not all published research has supported the above findings that 
black women are receiving delayed or guideline non-concordant endocrine therapy. For 
instance, the previously mentioned study by Foy et al. found that black women were 
more likely to receive hormonal therapy than white women (Foy et al. 2018). 
Additionally, multiple studies have published that black women are less likely to 
discontinue endocrine therapy than white women (Farias and Du 2017; Wheeler et al. 
2018). These contrasting results ultimately indicate that further research needs to be 
conducted regarding the initiation and continued use of endocrine therapy across 
races/ethnicities. 
Targeted Therapy 
 
The discovery of targeted therapy for HER2+ breast cancer, dramatically 
improved the chances of survival for women diagnosed with an aggressive subtype of 
cancer. This treatment advancement, however, has not been equally shared among all 
breast cancer patients. For instance, one study found that 40% of black patients with 
HER2+ cancer received trastuzumab within a year of diagnosis compared to 50% of 
white patients. This disparity was widened in stage III disease with 76% of white women 
receiving treatment and only 56% of black women. After adjusting for tumor 
characteristics, black women were 25% less likely to receive trastuzumab compared to 
white women (Reeder-Hayes et al. 2016). Trastuzumab and similar targeted treatments 
are the most effective treatment options for HER2+ breast cancer. The fact that not all 
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women are receiving the same rates of trastuzumab treatment sets a concerning precedent 
as trastuzumab is the standard of care for HER2+ breast cancer (Lukong 2017). 
Another factor that is important to consider in the use of HER2-targeted therapies 
is the risk of cardiotoxicity, often observed as a decrease in the left ventricular ejection 
fraction. Litvak and colleagues examined the racial differences in cardiotoxicity among 
216 patients with stage I - III HER2+ breast cancer treated at the Sidney Kimmel 
Comprehensive Cancer Center at Johns Hopkins. They discovered that black women had 
a higher rate of cardiotoxicity than white women. Overall, 10.2% of the study patients 
had to stop treatment due to cardiotoxicity which included 22% of black patients and 
5.7% of white patients. Ultimately, black patients had an odds ratio of 4.61 for not 
completing 52 weeks of therapy compared to white women (Litvak et al. 2018). 
Cardiotoxicity is an important concern when treating patients with HER2+ breast cancer 
that could potentially contribute to racial disparities in the receipt of targeted treatments 
among women.  
 
Clinical Disparities 
 
In addition to racial disparities in treatment options and initiation, black women 
are subject to different experiences in the clinic and as they interact with their healthcare 
providers. One aspect of care that is consistently under acknowledged is the direct impact 
of physicians on racial differences in the quality of care. One of the few studies analyzing 
the effect of physician variations on breast cancer care was conducted by Popescu and 
colleagues using the SEER-Medicare Database. The study indicated that physicians 
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treating majority black patient populations provided less guideline concordant care to all 
their patients than physicians who treat no black patients. Popescu et al. also found that 
differences in care between physicians accounted for less than 20% of the variation seen 
in treatment quality and did not account for the racial differences in observed care. 
However, variation in treatment provided by one physician for different patients 
accounted for over 70% of the differences in the applicable treatments (Popescu et al. 
2016). Additionally, Penner and colleagues conducted a study on oncologists and their 
black patients with breast, colorectal and lung cancer. Of the participants, 84% were 
breast cancer patients. Before meeting with patients for the first time, oncologists 
completed the Implicit Association Test (IAT) which screens for implicit racial bias. 
They found a negative association between providers’ implicit racial bias and the length 
of interactions with patients and ratings of supportive care. Providers with higher IAT 
scores were perceived as being less patient centered while communicating with black 
patients by independent observers and patients (Penner et al. 2016). It is important to 
recognize the potential impact that physician variation can have on racial disparities in 
breast cancer treatment. 
Notably, there are also racial differences in the patient populations of research 
studies. Research suggests that black women are less likely to be enrolled in clinical trials 
(Wheeler, Reeder-Hayes, and Carey 2013). This reduced enrollment in clinical trials may 
be the result of a complex history between medical institutions and black communities or 
possibly due to lower rates of outreach to black women for enrollment. Additionally, data 
from the Women Health Initiative Study found that larger portions of black women were 
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lost to follow up than white women during research (Livaudais et al. 2013). Nevertheless, 
the fact remains that if black women are not enrolled in clinical trials at the same rate as 
white women, they may not have access to the newest and most innovative treatments. 
Furthermore, due to this decreased enrollment of black women, the results of these 
clinical trials may not be applicable across all demographics.  
 
Individual-Level Barriers in Access to Quality Treatment 
 
In addition to barriers that patients face at the clinical level, patients also 
encounter barriers at the individual level. Cited barriers to care include diminished social 
support, medical mistrust, and financial obstacles (Ko et al. 2016). In 2014, Katz and 
colleagues published a study analyzing data from 1,995 patients with breast cancer from 
the Patient Navigation Research Program. Two thirds of these patients had at least one 
barrier to care and patients with at least one barrier to care had longer times to diagnostic 
resolution (Katz et al. 2014). Barriers included comorbidities, insurance, financial 
problems, housing issues, traveling, issues finding care for other adult’s in the patient’s 
life, and inaccessibility of care (Figure 9).  
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Figure 9: Frequency of Unique Barriers Among Breast Cancer Patients (Adapted 
from Katz et al. 2014).  
 
Furthermore, Freedman and colleagues conducted a qualitative analysis in which 
they interviewed 18 women treated for breast cancer at the Dana-Farber Cancer Institute 
and Columbia University Medical Center about their cancer care, treatment, and 
education. The research team found that 38.9% of the patients experienced treatment non-
initiation or delay due to reasons other than their provider suggesting they stop treatment. 
Major stated barriers for these women included transportation and childcare (Freedman et 
al. 2017). Patients also reported side effects from the medication as a key factor in early 
termination or missed treatment (Freedman et al. 2017). Furthermore, Jones and 
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colleagues conducted a systemic review of primary research published from 1991 to 2013 
examining barriers to diagnosis in black women. Black women across the studies were 
less familiar with the symptoms and risk factors of breast cancer and thus had lower 
perceptions of their risk for developing breast cancer than white women (Jones et al. 
2014). The study results also indicated that there was a correlation between the previous 
misdiagnosis of breast cancer symptoms in black women and a lack of confidence in their 
medical providers (Jones et al. 2014).  
Similarly, Paranjpe and colleagues completed a literature review of reported 
barriers to oral endocrine therapy adherence and continuation for patients with HR+ 
breast cancer. Results indicated that non-adherence and early discontinuation were 
strongly correlated to poor patient-provider relationships (Paranjpe et al. 2018) On the 
other hand, increased feelings of self-efficacy were correlated with higher rates of 
medication adherence. Ultimately, one of the largest reported barriers was the number of 
side effects from oral endocrine therapy (Paranjpe et al. 2018). Moreover, Wheeler and 
colleagues determined, based on data from the Carolina Breast Cancer Study, that lacking 
feelings of shared decision making and the belief that ET nonadherence does not impact 
health were highly predictive of ET underuse (Wheeler et al. 2018). Gallups and 
colleagues conducted research focused on black women with early stage breast cancer 
receiving chemotherapy in the ACTS (Adherence, Communication, Treatments and 
Support) Intervention Study. They found that comorbidities and employment status 
predicted treatment delays with unemployed patients having more treatment delays than 
employed patients (Gallups et al. 2018).  
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Among the barriers expressed by patients, insurance and financial concerns 
continue to be of high importance. Zafar and colleagues conducted a study on patients 
with solid tumors receiving chemotherapy or hormonal therapy, recruited from Duke 
University Medical Center and the HealthWell Foundation. Among the study patients, 
71% had breast cancer, 86% were women and 80% were white. Of the patients that 
completed diaries about their monthly costs, 55% were underinsured. Over 20% of 
patients reported not taking a prescription, underusing a prescription or only filling part 
of a prescription to help save money (Zafar et al. 2013). Underinsured patients and breast 
cancer patients overall are reporting concerning trends in access to care due to financial 
and insurance barriers. 
McGee and colleagues examined data from Phase III of the Carolina Breast 
Cancer Study for women with primary breast cancer and concluded that determinants of 
breast cancer treatment delay differ based on race (McGee et al. 2013). There was an 
association between immediate reconstruction surgery and delay for both white and black 
women. Other factors, however, such as losing one’s job and household size were 
associated with delays among the white women, while for black women, the delay was 
associated with the first course of treatment. Nonetheless, black women ages 20 to 49 
were three times as likely to experience delays than white women (McGee et al. 2013). 
Evidently, further research into the precise barriers affecting breast cancer treatment and 
their impact on racial disparities is warranted.    
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Interventions to Reduce Racial Disparities  
 
 As inequities in the receipt of care across all patient demographics continue to 
persist, public health officials have developed interventions to help mitigate these 
disparities. Providing patients with resources via patient navigators serves as a promising 
tactic for reducing disparities. The role of a patient navigator is to help patients 
throughout the process of their cancer treatment by offering assistance with 
transportation, interpreter services, child care, care coordination, financial resources and 
addressing other patient specific barriers to care (Paranjpe et al. 2018). Katz and 
colleagues documented the actions frequently taken by patient navigators on behalf of 
patients. Breast cancer patients most often needed assistance from navigators with 
scheduling appointments, helping with arrangements and making referrals (Figure 10). 
 
Figure 10: Patient Navigator Actions for Patients with Breast Cancer (Adapted 
from Katz et al. 2014). 
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A prospective meta-analysis by Battgalia and colleagues was conducted at six 
medical centers from the Patient Navigation Research Program, analyzing the impact of 
patient navigation on diagnostic resolution at 60, 180 and 365 days. Women that had an 
abnormal breast cancer scan (mammogram, ultrasound, MRI or breast mass indicative of 
cancer) were treated as usual or assigned to the patient navigator intervention (Battaglia 
et al. 2016). Navigation had no statistically significant effect at 60 or 180 days on 
achieving diagnostic resolution but patients in the navigation arm were twice as likely to 
achieve diagnostic resolution at 365 days than patients in the control arm (Battaglia et al. 
2016). The research team found that the patient navigation intervention was helpful 
across all races/ethnicities and likely beneficial for patients that might have been lost to 
follow up (Battaglia et al. 2016). In a similar study, Ko and colleagues analyzed data 
from seven Patient Navigator Research Program centers. Patients in the data set had a 
diagnosis of breast, colorectal, prostate or cervical cancer and 54% of the patients in the 
control arm and 48% in the navigation arm had breast cancer. For black patients, median 
days to resolution in the control group was 108, compared to 97 in the navigation arm. 
Black patients experienced a statistically significant delay in both the control group and 
navigation group, while there was no statistical difference between the non-Hispanic 
white group and Hispanic groups (Ko et al. 2016). Although additional research must be 
conducted, patient navigators serve as a promising initial step in the effort to reduce 
racial disparities.  
Another potential intervention to mediate racial disparities in breast cancer 
treatment is physician bias training. For example, Nelson and colleagues implemented a 
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training module of three 2-hour sessions to address the topics of race, racism, and 
whiteness in medicine. The study involved nineteen residents, the majority of which had 
received less than an hour of training regarding racism in medicine prior to the study. 
Following the training, 100% of the providers felt racism impacted health care delivery 
and white participants reported feeling less equipped to care for patients of color than 
prior to the intervention (Nelson, Prasad, and Hackman 2015). Similarly, Zeidan and 
colleagues implemented an educational intervention for twenty-one emergency medicine 
residents, including a grand round lecture on implicit bias, completing the IAT and a 
facilitated discussion of bias in emergency medicine. After the intervention, residents 
exhibited a 33.3% increase in awareness of their own implicit bias (Zeidan et al. 2019). 
While both these studies were conducted on a small scale, physician trainings on implicit 
bias and racism in medicine represent interventions with the potential to make a large 
positive impact.  
Lastly, city-wide initiatives focused on reducing the impact of healthcare 
disparities is another promising intervention. The city of Chicago can serve as a model 
for the potential of large-scale measures to make advancements in health equity. In the 
1980’s, breast cancer mortality rates were equal for black and white women in Chicago, 
but from the 1990’s until 2005, mortality rates diverged until black women were twice as 
likely to die from breast cancer than white women (Ansell et al. 2009). City officials, 
therefore, implemented the Metropolitan Chicago Breast Cancer Taskforce to elucidate 
the cause of higher rates of mortality for black women. They set out to determine if the 
disparity was due to lower rates of mammograms, poorer quality mammograms or 
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different treatments for black women with breast cancer. The task force determined that 
the primary issues included unequal access to screening, insufficient education and 
reduced quality of care (Ansell et al. 2009). Black women were more likely to have their 
mammograms performed at public institutions while white women were more likely to 
have them performed at private and academic medical facilities and have their 
mammograms read by radiology specialists (Ansell et al. 2009). To combat this growing 
disparity, the state of Illinois implemented a series of interventions including the Illinois 
Breast and Cervical Cancer Screening Program to pay for all mammograms and treatment 
of uninsured women, employing patient navigators and advocates, encouraging 
physicians to engage with black communities and remind women to get mammograms, 
targeting populations with educational media campaigns, increasing access and 
distribution of screening and treatment centers, creating a system for diagnostic follow up 
and training additional mammography specialists (Metropolitan Chicago Breast Cancer 
Taskforce. 2007). Approximately ten years later, Sighoko and colleagues analyzed the 
impact of the Metropolitan Chicago Breast Cancer Taskforce on healthcare disparities in 
Chicago compared to nine other cities across the US. They found that Chicago’s breast 
cancer mortality disparity reversed from increasing 3.9% annually in the years 1999 to 
2005 to decreasing 3.1% during the years 2006 to 2013. Excess deaths for black women 
from breast cancer decreased by 29% in Chicago while they increased by 22% in the US 
as whole in the years 2006-2013 compared to 1999-2005 (Sighoko et al. 2017). The city 
of Chicago serves as an example of the impact of powerful interventions on patient health 
outcomes.  
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DISCUSSION 
 
 The black-white racial disparity in the treatment of women with breast cancer is 
an important and complex issue. As the cancer affecting over 3.4 million women in the 
US, identifying the underlying causes of racial discrimination in breast cancer is essential 
to ensuring equal treatment of all patients (“Female Breast Cancer - Cancer Stat Facts” 
2018). Previous and ongoing research has identified numerous risk factors for breast 
cancer that impact minority populations disproportionately. Some of these risk factors are 
preventable, such as obesity or alcohol use, while others are more systemic such as the 
interplay between access to quality care and cancer survival outcomes. Black women 
tend to experience undue burden as a result of many factors, including insurance status, 
delays in treatment initiation and adherence, receiving guideline non-concordant care, 
and ultimately physician bias.  
Of stated risk factors, insurance status continues to pose a large barrier in access 
to equality in care. The research indicates that over 30% of the observed racial disparity 
can be attributed to differences in insurance status (Jemal et al. 2017). Hershman and 
colleagues found that on average, among patients with early stage breast cancer, black 
women were 4.1% more likely to have a higher copay than white patients for hormonal 
therapy medications (Hershman et al. 2015). Additionally, the data indicates that 
uninsured white women have higher rates of locoregional therapy than privately insured 
black women (Freedman et al. 2011). Lack of access to health insurance remains a 
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crippling source of racial disparities in treatments and outcomes. Healthcare disparities 
will persist as long as there is unequal access to quality care and insurance.  
 Another important aspect of breast cancer care that often differs along racial lines 
is tumor biology and characteristics. Black women consistently present with later stage, 
more aggressive tumors that have spread distally (Livaudais et al. 2013). This leads to the 
question – are black women being screened for breast cancer less often? There is some 
conflicting research as to whether black and white women have equal rates of 
mammography in this country. The most recently published literature, however, indicates 
that women are being screened equally for breast cancer across all races/ethnicities 
(Miller et al. 2017). This along with the molecular subtype distribution differences across 
races supports the conclusion that black women’s tumor biology is different (DeSantis et 
al. 2017). The concept of racial differences in tumor biology has been reinforced by 
research indicating that black women with West African heritage have a higher likelihood 
of developing TNBC (Newman and Kaljee 2017). Based on the interplay of breast cancer 
risk factors such as early menarche and increased parity, black women have a higher risk 
of developing aggressive, late stage breast cancer even with regular screening (Brawley 
2013).  
 Although the use of mammography appears to be equal amongst black and white 
women, axillary and sentinel lymph node biopsy is not. Sentinel lymph node biopsy after 
a positive mammogram has been the standard of care since the 1990’s (K. E. Reeder-
Hayes et al. 2011). SLNB continues to be an essential step in the staging process of a 
breast cancer diagnosis. Black women, however, are not receiving SLNB at the same 
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rates as their white counterparts (Bickell et al. 2006). The reduced rates of SLNB could 
result in an inaccurate diagnosis and, therefore, treatment course for patients’ specific 
breast cancer. Increasing rates of SLNB to guideline standards should be a priority for 
decreasing racial disparities in breast cancer care.  
Across all regularly used treatment options, the medical literature has identified 
racial disparities in some but not all breast cancer treatments. One treatment option in 
which there is strong evidence to indicate that black women are not receiving the same 
caliber of care is surgery, including breast conserving surgery and mastectomy. The 
published literature reveals that black women are less likely to receive surgery than their 
white counter parts (Foy et al. 2018; Jemal et al. 2017). Moreover, black women 
experience longer delays until the initiation of surgical treatment (Eaglehouse et al. 
2019). The literature presents a clear racial disparity in the receipt of surgery amongst 
black breast cancer patients. 
Radiation therapy is another aspect of breast cancer care that is being systemically 
underutilized in the treatment of black women. An extensive backdrop of literature 
confirms that black women categorized by stage and cancer subtype are less likely to 
receive guideline concordant radiation therapy than their white peers (Foy et al. 2018; 
Ooi, Martinez, and Li 2011). Across ages, subtypes and stages, black women are less 
likely to receive radiation therapy after BCS or mastectomy and they experience a higher 
probability of delayed access to radiation therapy (Wheeler et al. 2012). Wheeler and 
colleagues also suggest that part of the racial disparity in receipt of radiation therapy 
involves distance to a clinic or hospital offering radiation therapy. It is possible that black 
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patients whom tend to be of lower SES live in communities that are not equipped with the 
latest oncological technology so they must travel further, experiencing transportation 
barriers that prevent them from accessing radiation therapy in a timely manner.  
Chemotherapy is one of the oldest forms of treatment for all cancers including 
breast cancer. Because chemotherapy has been used to treat cancer for many decades, its 
implementation is widespread. Although some of the published literature has deemed 
black women less likely to receive chemotherapy or adjuvant chemotherapy, the majority 
of research has indicated the opposite. In fact, several studies have found that black 
women were equally if not slightly more likely to receive chemotherapy treatment than 
white women (Hoppe et al. 2018; Enewold et al. 2018; Simon et al. 2012). The 
widespread adoption of chemotherapy can serve as a guide for establishing equal access 
to care across all races/ethnicities. 
One of the largest treatment disparities is the underuse or non-guideline 
concordant administration of endocrine therapy for HR+ breast cancer. Previous research 
has identified the primary treatment issues as including delayed initiation, underuse and 
non-adherence, all problems extensively documented in several studies’ black patient 
populations (Wheeler et al. 2018; Farias and Du 2017; Bickell et al. 2006). Some aspects 
of ET underuse can be attributed to the finding that patients were more likely to miss or 
underuse ET if they did not believe it had any effect on recurrence of breast cancer 
(Wheeler et al. 2018). Wheeler and colleagues found the belief among patients that ET 
adherence does not impact health predicted nonadherence to treatment (Wheeler et al. 
2018). This further iterates the point that patient education is of the utmost importance 
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and health care providers must equip patients with the resources to adhere to treatment 
regimes.  
 At the moment, targeted therapy is the frontline of breast cancer treatment. The 
utilization of targeted therapy can represent the accessibility of novel treatment options 
for black patients. The use of targeted therapy by black women, however, does not offer 
promising statistics. Black women are significantly less likely to receive targeted therapy 
such as trastuzumab, and of those whom did, there were significant delays in treatment 
initiation (K. Reeder-Hayes et al. 2016). Additionally, black patients experienced higher 
rates of cardiotoxicity which likely result in treatment delays and discontinuation (Litvak 
et al. 2018). There are currently very few publications focusing on the racial differences 
in the use of HER2-inhibitors and targeted therapy. The racial disparities in the access to 
this novel treatment should serve as a focus of future research as it provides a unique 
insight on the implementation of newly developed treatment options. 
 Individual barriers to care serve as one of the most concerning aspects of racial 
disparities in the treatment of women with breast cancer. Major cited barriers to care 
among women with breast cancer include transportation, childcare, side effects from 
medications, familiarity with symptoms and risk factors of breast cancer, provider 
mistrust and miscommunication, lacking feelings of shared decision making, 
comorbidities, unemployment, financial concerns and insurance coverage (Freedman et 
al. 2017; Jones et al. 2014; Paranjpe et al. 2018; Wheeler et al. 2018; Gallups et al. 2018; 
Zafar et al. 2013). Although not all referenced studies specifically focused on black 
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women, these stated barriers provide useful insight regarding aspects of care to target 
with individual and system-level interventions.  
While analyzing the published literature, it is important to take several key points 
and limitations into consideration. First of all, much of the data presented in the literature 
was collected prior to 2011. It can be difficult to evaluate the current trends in treatment 
utilization and patient outcomes from years past. It may require additional time for 
guidelines to be implemented so there could be a substantial delay in the receipt of 
guideline-concordant therapy. Nevertheless, if a racial disparity in the treatment of breast 
cancer was present several years prior to research publication, it is not unreasonable to 
conclude that such racial differences are likely still present. Therefore, it is important to 
note the years from which a publication’s data is derived but understand that the 
implications are still widely applicable.  
Furthermore, much of the published research places an emphasis on an older 
patient population. Many studies drew from the SEER-Medicare database which 
predominantly includes patients 65 years of age and older. While this is a useful tool in 
minimizing the impact of insurance on witnessed disparities, it fails to capture younger 
patients in the analysis. This younger demographic is particularly important when 
analyzing racial disparities in the treatment of breast cancer primarily because black 
women have a higher occurrence of aggressive TNBC at a younger age. It is particularly 
important that this population of young black women is included in research to help 
elucidate factors contributing to the unequal distribution of breast cancer subtypes. 
Additionally, younger patients overall have more variability in their insurance status and 
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a patient’s insurance coverage ultimately has a substantial impact on their treatment 
course. Therefore, it is important to analyze the impact of insurance status on care. As a 
result, there is a greater need for breast cancer research focusing on younger patient 
populations as opposed to older patients found in the SEER-Medicare Database.  
Additionally, one of the largest limiting factors pertaining to racial disparity 
research is the retrospective nature of most studies. A large portion of the research on 
racial disparities and breast cancer in the US stems from the SEER or SEER-Medicare 
databases. Extensive use of the SEER databases means a majority of the published 
research is retrospective and correlational. Retrospective studies can help guide the 
research to formulate hypotheses on which factors contribute to racial disparity in the 
treatment of breast cancer, but there is a need for prospective studies in the field. 
Additional prospective trials will ultimately prove the most effective by focusing on 
interventions such as patient navigation to alleviate established racial differences in care. 
It is important to advance breast cancer research beyond the widely accessible SEER 
databases to explore causation in breast cancer racial disparities.  
Furthermore, there are specific areas of the published literature that need be 
expanded upon. Foremost, future research should concentrate on the receipt of HER2+ 
therapy and hormone receptor testing. As targeted therapy for HER2+ breast cancer is a 
newer treatment option, there is ample room to study new interventions to mitigate the 
trend of racial inequality in healthcare. Specifically, research should ensure that black 
women are receiving the same access to care, and if not, explore effective interventions to 
help eliminate this issue. Another area of research that should be further explored is the 
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rate of hormone receptor testing across all races/ethnicities. Freedman and colleagues did 
find high rates of hormone receptor testing across all races and ethnicities analyzing data 
from 1998 – 2005 (Freedman et al. 2011). However, since hormone receptor testing is 
such an essential component of the breast cancer diagnosis it must be studied further. If 
patients are not being tested for hormone receptors, they are put at an inherent 
disadvantage and become unlikely to receive the most effective treatment course for their 
cancer.  
While many systemic factors contribute to racial differences in quality of care 
such as tumor biology, insurance status and comorbidities, the role of physicians’ implicit 
bias or explicit bias when treating minority patients has been demonstrated to contribute 
to poor outcomes among black women. Popescu and colleagues found that differences in 
how physicians treat individual patients accounted for almost 80% of the treatment 
variations for breast cancer patients (Popescu et al. 2016). Similarly, prospective trials 
indicated that oncologists with higher ratings of implicit bias spent less time with their 
patients and objectively provided less supportive, patient-centered care (Penner et al. 
2016). The effect of physician bias on the treatment of patients across all races/ethnicities 
deserves further attention. Preliminary research demonstrated that after implementing 
physician bias training, residents reported increased awareness of the impact of racism in 
medicine and the effects of their own implicit bias (Zeidan et al. 2019; Nelson, Prasad, 
and Hackman 2015). Future research should prospectively introduce physician trainings 
on racial bias and analyze the impact of such interventions on healthcare disparities. 
Racial disparities in the treatment of black women with breast cancer have persisted for 
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decades, and have even widened in recent years with breast cancer incidence rates 
increasing for black women (DeSantis et al. 2017). Eliminating racial disparities in the 
clinic should serve as a focus of future research and interventions. Opportunities for 
reducing these disparities include both systemic and provider-based approaches.  
Ultimately, one of the most important areas of future research is the impact of 
extensive interventions on mitigating racial disparities. For example, patient navigators 
serve a vital role in ensuring equal access to care by working to keep patients previously 
lost to follow up within the medical system (Battaglia et al. 2016). Patient navigators can 
also work with patients on an individual level to address many of the previously 
discussed barriers to breast cancer treatment (Katz et al. 2014). As patient navigators 
become more prominent in the field of oncology, future studies should aim to identify 
vulnerable populations most in need of assistance and the patient navigator actions most 
effective in reducing racial disparities. Equally promising in the field of public health is 
the potential of city-wide initiatives and referendums to address inequities as 
demonstrated by the reversal in mortality rates among black women in the city of 
Chicago (Ansell et al. 2009; Sighoko et al. 2017). Public health officials and research 
teams aiming to reduce racial disparities should note the profound impact that city-wide 
initiatives had on reducing health inequities. The city of Chicago can serve as a model for 
future research on mitigating racial disparities in diverse communities. Patient navigators 
and city-led initiatives are two promising interventions on the path to health equity.  
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CONCLUSION 
 
  Despite years of study, racial disparities in the treatment of black women with 
breast cancer continue to persist. There is an extensive body of published literature 
indicating racial disparities in the use of sentinel lymph node biopsy, surgery, radiation 
therapy, hormone therapy and targeted therapy. The equal receipt of chemotherapy and 
screening mammography offer promise of future equity as these two treatments are 
uniquely implemented across all races/ethnicities. The effective application of patient 
navigators, physician bias training and city-wide initiatives to address racial disparities 
should serve as guidelines for future interventions. Racial disparities in healthcare are a 
complex topic. Nevertheless, as long as inequities exist in the treatment of patients along 
racial/ethnic divisions, the study of racial disparities in healthcare must continue.  
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